Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Advances in the management of higher-risk myelodysplastic syndromes: future prospects.

Leukemia & lymphoma - 1 Sept 2024

Gener-Ricos Georgina, Rodriguez-Sevilla Juan Jose, Urrutia Samuel, Bataller Alex, Bazinet Alexandre, Garcia-Manero Guillermo

Abstract excerpt

Higher-risk myelodysplastic syndromes (HR-MDS) are defined using a number of prognostic scoring systems that include the degree of cytopenias, percentage of blasts, cytogenetic alterations, and more recently genomic data. HR-MDS encompasses characteristics such as progressive cytopenias, increased bone marrow blasts, unfavorable cytogenetics, and an adverse mutational profile. Survival is generally poor, and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Combined Modality Therapy
Share to Disease Management

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to DNA Methylation

Share to Hematopoietic Stem Cell Transplantation

Share to Mutation

Share to Myelodysplastic Syndromes

Share to Prognosis

Share to Treatment Outcome

Source

Identifiers

PMID: 38712556
DOI: 10.1080/10428194.2024.2344061

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Advances in the management of higher-risk myelodysplastic syndromes: future prospects.PMID 38712556Read ↗

How I treat higher-risk MDSSemantic proximity Read ↗

Predicting outcome in higher-risk myelodysplastic syndrome patients treated with azacitidine.Semantic proximity Read ↗

Current therapeutic approaches for patients with myelodysplastic syndromes.Semantic proximity Read ↗

Management of higher risk myelodysplastic syndromes after hypomethylating agents failure: are we about to exit the black hole?Semantic proximity Read ↗

Molecular Targeted Therapy and Immunotherapy for Myelodysplastic SyndromeSemantic proximity Read ↗

Myelodysplastic syndromes.Semantic proximity Read ↗

Current and emerging strategies for management of myelodysplastic syndromes.Semantic proximity Read ↗

Understanding the Continuum between High-Risk Myelodysplastic Syndrome and Acute Myeloid Leukemia.Semantic proximity Read ↗

Myelodysplastic Syndromes, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology.Semantic proximity Read ↗

Myelodysplastic syndromes: recent advancements in risk stratification and unmet therapeutic challenges.Semantic proximity Read ↗

Myelodysplastic syndromes: Updates on Genomic Landscape, Molecular Subtypes, & Targeted Therapies.Semantic proximity Read ↗

Life after hypomethylating agents in myelodysplastic syndrome: new strategies.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.